S
exual transmitted infections (STIs) are a significant health care crisis, with 20 million new STIs occurring in the United States each year. 1 Chlamydia and gonorrhea, the 2 most commonly reported STIs, can progress to pelvic inflammatory disease potentially causing infertility and other lifelong health complications if left untreated. It is imperative to provide appropriate treatment to patients and their partners to prevent future health complications.
Expedited partner therapy (EPT) is effective at preventing reinfection of chlamydia and gonorrhea. 2 Expedited partner therapy allows providers to give their patients diagnosed as having chlamydia or gonorrhea prescriptions or medications to give directly to their partner; thus, the partner does not need to see a health care provider. 2 It should be used if the partner is unlikely to seek care. Expedited partner therapy has been recommended by the Centers for Disease Control and Prevention since 2006 because it reduces the risk of persistent or reinfection of chlamydia and gonorrhea compared with standard referral. 2 It has also been endorsed by the American Academy of Pediatrics, the American Academy of Family Physicians, the American Congress of Obstetricians and Gynecologists, and the Society of Adolescent Health and Medicine. [3] [4] [5] [6] Despite recommendations for EPT by numerous medical organizations, as of publication, it is currently protected by law in only 41 states and specifically against the law in 2. 7 In the remaining 7 states, EPT is potentially allowable, which means that there are no specific statutes addressing EPT or EPT is subject to additional policies. 7 In addition, laws governing allowable EPT prescribing practices vary by state. For example, in Wisconsin, EPT has been legal since 2010 and laws allow EPT prescriptions to be "nameless" if the patient does not know or will not disclose the partner's name. 8, 9 The provider can simply write "expedited partner therapy" on the prescription. 2 Expedited partner therapy is especially important in Wisconsin because the most recent available Centers for Disease Control and Prevention data ranked Milwaukee first for rate of gonorrhea and fourth for chlamydia in the United States. 1 Milwaukee County has nearly 1 million residents and is highly segregated, with the suburbs being predominately white and the city predominately nonwhite. 10, 11 Minorities in Milwaukee are disproportionally affected by STIs, with blacks having more than 9 times the rate of chlamydia and 20 times the rate of gonorrhea compared with whites. 12 The success of prescription EPT requires action on the part of the provider, patient, partner, and pharmacist. Although many studies demonstrate that providers lack knowledge of and underuse EPT, [13] [14] [15] there is little literature regarding pharmacist knowledge and use of EPT. A New York City survey conducted in 2012, and repeated in 2014, consistently showed that less than half of pharmacists knew that EPTwas legal. 16 There are no known studies accessing the pharmacist acceptance of EPT, defined by actual observation of whether pharmacists fill EPT prescriptions.
The objective of this study was to determine the percentage of nameless EPT prescriptions that Milwaukee County pharmacists refused to fill through "secret shopper" interactions. Because of the racial segregation in Milwaukee County and racial disparities of STIs, our hypotheses were that nameless EPT prescriptions were more likely to be refused at pharmacies located in the suburbs compared with the city of Milwaukee and more likely to be refused if the patient was nonwhite.
MATERIALS AND METHODS
This was a cross-sectional study conducted at one local pharmacy chain in Milwaukee County. All 50 pharmacies locations within the county were included. Three trained research assistants who varied in sex, age, and race posed as "patients." Patient A was a white women younger than 30 years, patient B was a nonwhite man younger than 30 year, and patient C was a nonwhite woman older than 50 years. Each pharmacy location was visited once by one patient with nameless prescriptions for azithromycin and cefixime, the recommended oral medications to treat chlamydia and gonorrhea. The encounters were semiscripted. At each pharmacy, the patient asked to speak directly with a pharmacist. The patient then presented the nameless EPT prescription to the pharmacist and asked if it could be filled. If the pharmacist agreed to fill the prescription, the patient requested the prescription back insisting he/she changed his/her mind and wished to instead speak with his/her physician first, thus ending the encounter. If the pharmacist refused, the patient asked the reason for prescription refusal and offered solutions to troubleshoot. For example, if told the issue was insurance/cost, the patient offered to pay out of pocket. If the pharmacist told the patient they needed a name, the patient said his/her partner's physician said that a name would not be needed. After troubleshooting and offering solutions, a second attempt was made and the pharmacist either agreed to fill or continued to refuse the prescription (Fig. 1) . No medications were dispensed during the entirety of the study. Encounters occurred for 6 days in December 2016. This study was approved by the Medical College of Wisconsin's institutional review board as a deception study requiring the approval of the pharmacy's regional supervisor with assurance that no staff employment would be jeopardized should they not fill the prescriptions. After each site was visited, the institutional review board required a letter sent to each site manager notifying them of the study and allowing them a chance to have their site's data withdrawn from the study. After leaving the pharmacy, the patients immediately recorded the outcome of prescription refusal and refusal reason. Additional data collected included pharmacy location (categorized as Milwaukee city vs. suburban), 24-hour pharmacy status, day of encounter (categorized as weekend vs. weekday), time of encounter (categorized as morning, afternoon, or evening), and perceived pharmacist characteristics including sex, age group (<30, 30-50, and >50 years), and race (white or nonwhite). We recorded whether the pharmacist refused to fill the prescription on the first and second requests. The primary outcome was refusal on the first request, and we analyzed characteristics associated with refusal on the first request. We chose refusal on the first request as the primary outcome because in real circumstances, patients may not ask why their prescription was refused; therefore, the encounter may not progress to allow for a second chance for refusal. χ 2 Test and Fisher exact test were used to compare categorical variables, using an α of 0.05. Multiple logistic regression using stepwise selection and an α of 0.05 was used to identify factors associated with prescription refusal. Effects considered for inclusion in the model were as follows: pharmacy location; 24-hour pharmacy status; day of encounter; perceived pharmacist, age, and race; patient sex, age, and race; and pharmacist-patient sex, age, and race comparisons, along with 2-way interactions. Statistical analysis was done using SAS V 9.2 (SAS, Cary, NC). Figure 1 . Flow diagram of the patient-pharmacist encounter. *In total, after first and second attempts, 26 (52%) nameless EPT prescriptions were refused, whereas 24 (48%) were accepted. †All 3 prescriptions came from the insurance/cost category after the patient offered to pay out of pocket.
RESULTS
Of the 50 encounters, 29 (58%) patients were initially refused and 21 (42%) were able to fill the prescription on the first attempt (Fig. 1) . No pharmacies opted to withdraw data. Reasons for refusal were categorized and are listed in Figure 1 . After troubleshooting, only 3 additional prescriptions were accepted (all from the insurance/cost category); therefore, 26 (52%) of EPT prescriptions were refused by pharmacists (Fig. 1) .
Perceived pharmacy and pharmacist characteristics are included in Table 1 . Prescriptions were more likely to be refused if the pharmacy was located in the suburbs (77%) compared with the city of Milwaukee (43%; P = 0.01). No pharmacist characteristics were associated with prescription refusal. Analysis of patient characteristics, also in Table 1 , showed that the prescription was more likely to be refused if the patient was white (78%) compared with nonwhite (47%; P = 0.03). Comparisons between the pharmacist and the patient are presented in Table 2 . The prescription was more likely to be refused if the pharmacist was older than the patient (82%) compared with the pharmacist being younger than the patient (46%) or within the same age group (33%; P = 0.01).
In a multivariate analysis, prescriptions were more likely to be refused if the pharmacy was located in the suburbs compared with the city of Milwaukee (odds ratio, 5.3; 95% confidence interval, 1.4-20.3; P = 0.03) and if the patient was white compared with nonwhite (odds ratio, 4.8; 95% confidence interval, 1.2-19.8; P = 0.01). Not significant were 24-hour pharmacy status; day of encounter; perceived pharmacist sex, age, and race; patient sex and age; and pharmacist-patient sex, age, and race comparisons.
DISCUSSION
This is the first known study that assesses the acceptance or refusal of nameless EPT prescription through in-person encounters. Although prescription and medication EPT is a legal practice in Wisconsin since 2010, in this study, more than half of the nameless EPT prescriptions were refused. The most common reason cited for refusal was a lack of name for legal purposes. Because in Wisconsin, a name is not required for legal purposes and the law protects providers and pharmacists from liability, the need for improved knowledge about the specific name details of EPT was highlighted through this study. Even after our patients encouraged the pharmacists by stating that the prescribing physician said a name was not required, no pharmacist sought to look up the EPT law or allowed the prescription to be filled. The only 3 prescriptions that were allowed after "troubleshooting" were for insurance/cost reasons; still, more than half were refused.
In this study, no pharmacist characteristics were associated with EPT refusal, including perceived age group. This finding suggests that pharmacists' understanding of EPT guidelines does not vary depending on when they received their training. We were not surprised by the increased refusal in suburban pharmacies. We hypothesized this because the rates of STIs are significantly higher in minorities and Milwaukee is one of the most segregated areas in the United States, with most minorities residing in the city compared with the suburbs. 1, 17 Because STI rates are higher in the city, it is likely that pharmacists located in Milwaukee have encountered EPT more frequently and would thus be more likely to fill the prescription. We had also hypothesized that pharmacists would be more likely to refuse nameless prescriptions from nonwhite patients compared with white patients. This was based on many studies including a systemic review by Hall et al. showing that health care workers have an implicit bias of negative attitudes toward nonwhites and positive attitudes toward whites. [18] [19] [20] However, in our study, the prescription was more likely to be refused when the patient was white. A possible explanation is higher expectations/ standards for patients who are white and thus disapproval when EPT is requested. 21 The etiology of the known racial disparities of STIs is multifactorial and should be further investigated. Additional EPT education for pharmacists would increase overall awareness of EPT and ultimately the ability for patients to fill prescriptions.
This study has limitations. The patient always first asked to speak directly with a pharmacist. This was necessary to determine the pharmacist's understanding of EPT guidelines, but eliminated the initial interaction with the pharmacist technician who may have less knowledge of EPT. Therefore, it is plausible that our study resulted in a lower refusal rate than what might be encountered by actual patients. Further studies would be needed to assess if further EPT training for pharmacist technicians would also be beneficial. Also, this study was limited to one pharmacy chain in one county. However, the pharmacy chain is among the largest in the county and is nationally available.
In conclusion, although a legal practice in Wisconsin, nameless EPT prescriptions are refused more than half the time at the pharmacy. Although it is imperative that medical providers have increased knowledge and utilization of nameless EPT prescriptions, without increased acceptance of these prescriptions at pharmacies, nameless EPT will never be successful at reducing reinfection rates of chlamydia/gonorrhea in the real world. It is important to increase pharmacist awareness and educate about EPT to ultimately increase success of EPT.
